The joint proposal aligns strategic interests between A2 Milk, which holds a 19.8 percent minority stake in Synlait, and Fonterra, which is positioned as a funding and operational partner. For A2 Milk, securing control over Synlait addresses critical supply chain vulnerabilities tied to the Chinese regulatory environment. Synlait’s flagship Dunsandel facility in Canterbury holds the vital State Administration for Market Regulation (SAMR) registration required to manufacture A2 Milk’s China-label infant milk formula (IMF), a product line accounting for nearly half of A2 Milk’s total infant formula sales.

Synlait has faced ongoing financial pressure despite recent capital injections and debt restructuring. The company’s 65 percent controlling shareholder, Chinese state-owned Bright Dairy and Food, previously intervened to recapitalize operations, supported by a $NZ320 million banking syndicate refinancing and a$NZ130 million replacement shareholder loan. To manage liquidity constraints and reduce debt, Synlait has engaged in asset divestments, including the $NZ307 million sale of its Pokeno manufacturing plant in the North Island to Abbott, alongside the departure of chief executive Richard Wyeth.

For Fonterra, the acquisition aligns with its refined corporate strategy under chief executive Richard Allen, who succeeded Miles Hurrell in May. Following the $3.3 billion divestment of its global consumer brands and ingredients businesses to Lactalis, the cooperative has concentrated resources on business-to-business processing scale, milk pool optimization, and specialized ingredients. Absorbing Synlait’s Dunsandel hub—which collects over 800 million litres of milk annually and produces 450 to 500 tonnes of powder daily—would eliminate a regional processing competitor while securing valuable Canterbury milk flows.